Moreover, neurological adverse events—including encephalopathy, seizures, and speech disturbances—occur in over 50% of treated patients and are thought to result from CD19 expression on certain neuronal subpopulations (174, 176). This evidence concerns the gene CD19 and Encephalopathy.